ASIT biotech Reviews the Efficacy Results of gp-ASIT+™ Observed During the Phase III Trial Completed in 2016

BRUSSELS--()--Regulatory News:

  Pollen peak   Whole season

Number of
patients

  Clinical efficacy

Number of
patients

  Clinical efficacy
    Placebo   Treated  

Reduction in
CSMS3

  P value   Placebo   Treated  

Reduction in
CSMS3

  P value
All patients1 136   264 -15.5%   0.04 95   201 -17.9%   0.03
The most affected patients (50% total population)1 67 136 -19.8% 0.05 46 108 -24.4% 0.05
Patients recruited in Belgium2   13   24   -35.1%   0.03   8   12   -53.7%   ns
1 R. Mösges et al EAACI 2017
2 M. Shamji et al EAACI 2017
3 CSMS: Combined Symptom and Medication Score

4 ns: non significant

ASIT biotech (ASIT - BE0974289218) (Paris:ASIT) (BSE:ASIT), a Belgian biopharmaceutical company specialising in allergen immunotherapy, reviews and details the results of the first Phase III trial with gp-ASIT+presented by Professor R. Mösges (University of Cologne) and Professor M. Shamji (Imperial College London) at the 2017 Annual EAACI Congress (European Academy of Allergy and Clinical Immunology).

The efficacy of gp-ASIT+ is measured by the reduction in symptoms and the intake of common rescue medications like antihistamines or intranasal corticosteroids during the pollen season. This is referred to as a reduction in the Combined Symptom and Medication Score (CSMS). This score is calculated on the basis of data on symptoms and medication use recorded every day in a diary by each patient.

The results presented to the EAACI show that over the course of the whole pollen season, gp-ASIT+ resulted in an average reduction in the combined score of 17.9% for the entire study population, close to the threshold of 20% required by the registration authorities. The effects of gp-ASIT+ were greater and exceeded this threshold of 20% (24.4%) for the most allergic group of patients (representing 50% of the total population). These effects were even more marked (53.7%) for patients recruited in Belgium

The differences in efficacy between these groups of patients are linked to variability in the severity of their allergy as well as differences in pollen levels between the regions of Europe in which the study was conducted. The exceptional results achieved in Belgium can be explained by the optimum combination of patients who were severely allergic and a normal season in terms of grass pollen exposure.

This optimum combination in Belgium created the best possible conditions for conducting the study into the immunological mechanism of gp-ASIT+ as initially planned. This study showed that gp-ASIT+ was capable of achieving development of an optimal immune tolerance in only 3 weeks, whereas competing products take months, or even years, of treatment to achieve comparable results.

The results of this first study in Phase III confirm that gp-ASIT+ is capable of achieving a reduction in the combined score above the threshold of 20% demanded by the registration authorities. In view of this, for its next clinical trials with gp-ASIT+, ASIT biotech has decided to maximize chances of success, in particular by using electronic diaries to significantly improve patient monitoring and by recruiting more patients with a severe allergy.

Within this context, the latest response from the FDA, which focuses on a limited number of clarifications on the gp-ASIT+master file, can be seen as a positive, significant advance in the definition of the clinical development plan in the United States. This development plan will be discussed at a meeting with the FDA.

***

About Ralph Mösges & Mohamed Shamji

https://www.asitbiotech.com/company/scientific-committee

About ASIT biotech

ASIT biotech is a Belgian clinical stage biopharmaceutical company focused on the development and future commercialisation of a range of breakthrough immunotherapy products for the treatment of allergies. Thanks to its innovative ASIT+™ technology platform, ASIT biotech is currently the only developer of AIT product candidates consisting of a unique mixture of highly purified natural allergen fragments in an optimal size selection. This innovation results in a short treatment, expected to improve patient compliance and real-life effectiveness. ASIT biotech’s product pipeline entails two novel ASIT+™ product candidates targeting respiratory allergy with the highest prevalence (i.e. grass pollen: gp-ASIT+™ and house dust mite: hdm-ASIT+™), that could significantly expand the current immunotherapy market. The Company believes that its innovative ASIT+™ platform is flexible and would be applicable across a range of allergies.

ASIT biotech has a headcount of 22 staff members, at its headquarters in Brussels and a laboratory in Liège, Belgium.

Further information can be found at: www.asitbiotech.com.

Forward Looking Statements

All statements in this announcement that do not relate to historical facts and events are “forward-looking statements”. In some cases, these forward-looking statements can be identified by the use of forward-looking terminology, including the words “believes,” “estimates,” “anticipates,” “expects,” “intends,” “may,” “will,” “plans,” “continue,” “ongoing,” “potential,” “predict,” “project,” “target,” “seek” or “should” or, in each case, their negative or other variations or comparable terminology or by discussions of strategies, plans, objectives, targets, goals, future events or intentions. Forward-looking statements include statements regarding the Company’s intentions, beliefs or current expectations. By their nature, forward-looking statements involve known and unknown risks and uncertainties because they relate to events and depend on circumstances that may or may not occur in the future. Forward-looking statements are not guarantees of future performance. Given these risks and uncertainties, you should not rely on forward-looking statements as a prediction of actual results. Any forward-looking statements are made only as of the date of this announcement and, without prejudice to the Company’s obligations under applicable law in relation to disclosure and ongoing information, the Company does not intend, and does not assume any obligation, to update the forward-looking statements set forth in this announcement.

Important Legal Notice

This announcement does not constitute, or form part of, an offer or invitation to sell or issue, or any solicitation of an offer to purchase or subscribe for shares of ASIT biotech SA (the “Company” and the “Shares”). Any purchase of, subscription for or application for, Shares to be issued in connection with the intended offering should only be made on the basis of information contained in the prospectus and any supplements thereto, as the case may be. This announcement does not constitute a prospectus and the information contained herein is for information purposes only and does not purport to be full or complete. Investors should not subscribe for any Shares except on the basis of the information contained in the prospectus that the Company expects to publish after its approval by the Belgian Financial Services and Markets Authority, and which can then be obtained at the Company’s registered office and on www.asitbiotech.com.

This announcement is not for distribution, directly or indirectly, in or into the United States or to any U.S. person within the meaning of the U.S. Securities Act of 1933, as amended (the “Securities Act”). The Shares have not been and will not be registered under the Securities Act and may not be offered or sold in the United States, except pursuant to an exemption from the registration requirements of the Securities Act. The Company has not registered, and does not intend to register, any portion of the intended offering of Shares in the United States, and does not intend to conduct a public offering of Shares in the United States.

This announcement and the information contained herein are not for publication, distribution or release in or into the United States, Australia, Canada, Japan or any jurisdiction where to do so would constitute a violation of the relevant laws of such jurisdiction.

The Company is responsible for the information contained in this press release.

Contacts

ASIT biotech
Thierry Legon, Tel. +32 2 264 03 90
CEO
investors@asitbiotech.com
or
Media and Investor Relations - France
NewCap
Dusan Oresansky / Pierre Laurent, Tel.: +33 1 44 71 94 92
asitbiotech@newcap.eu
or
Media Relations - Belgium
Laure-Eve Monfort, Tel.: +32 2 290 90 93
monfort@comfi.be

Contacts

ASIT biotech
Thierry Legon, Tel. +32 2 264 03 90
CEO
investors@asitbiotech.com
or
Media and Investor Relations - France
NewCap
Dusan Oresansky / Pierre Laurent, Tel.: +33 1 44 71 94 92
asitbiotech@newcap.eu
or
Media Relations - Belgium
Laure-Eve Monfort, Tel.: +32 2 290 90 93
monfort@comfi.be